FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gregory Riely

Research Profile

Disorders

Chemicals & Drugs

Physiology

Concepts & Ideas

Activities & Behaviors

Smoking

Genes & Molecular Sequences

Genes, erbB-1

Procedures

Co-author Network

Publications

TOP 3
William D Travis; Elisabeth Brambilla; Gregory J Riely
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.
Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Helena A Yu; Gregory J Riely
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gregory Riely (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: William D Travis; Elisabeth Brambilla; Gregory J Riely
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(8):992-1001.
2013: Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(3):346-51.
2013: Helena A Yu; Gregory J Riely
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Journal of the National Comprehensive Cancer Network : JNCCN 2013;11(2):161-9.
2013: Anna M Varghese; Jamie E Chaft; Melissa L Johnson; Marc Ladanyi; Gregory J Riely; Camelia S Sima; Mark G Kris
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(1):123-5.
2012: Sandra P D'Angelo; Joseph Dycoco; Yelena Y Janjigian; Mark G Kris; Marc Ladanyi; Gregory J Riely; Valerie W Rusch; Ronglai Shen; Camelia S Sima; Maureen F Zakowski; Junting Zheng; Nicholas Ahye; Jamie E Chaft; Christopher G Azzoli
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(12):1815-22.
2012: Paul K Paik; Camelia S Sima; Daphne Ang; Sandra P D'Angelo; Snjezana Dogan; Melissa L Johnson; Mark G Kris; Marc Ladanyi; Vincent A Miller; Gregory J Riely
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Cancer 2012;118(23):5840-7.
2012: Snjezana Dogan; Melissa L Johnson; Mark G Kris; Paul K Paik; Gregory J Riely; Ronglai Shen; Maureen F Zakowski; Daphne C Ang; Edyta B Brzostowski; Sandra P D'Angelo; Marc Ladanyi
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6169-77.
2012: Helena A Yu; Gregory J Riely
Who should receive EGFR tyrosine-kinase inhibitors?
The lancet oncology 2012;13(11):1074-6.
2012: Ken Takezawa; Valentina Pirazzoli; Katerina Politi; Gregory J Riely; Xiaoling Song; Paula J Spitzler; Maria E Arcila; Elisa de Stanchina; Yelena Y Janjigian; Mark G Kris; Marc Ladanyi; Mary Ann Melnick; Vincent A Miller; Caroline A Nebhan; Kadoaki Ohashi; William Pao
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Cancer discovery 2012;2(10):922-33.
2012: D Ross Camidge; Jeffrey W Clark; Daniel B Costa; Jeffrey A Engelman; Panagiotis Fidias; Stephen B Fox; Leena Gandhi; A John Iafrate; Pasi A Janne; Dong-Wan Kim; Eunice L Kwak; Patricia M LoRusso; Sai-Hong I Ou; Gregory J Riely; Katherine Ruffner; Ravi Salgia; Geoffrey I Shapiro; Benjamin Solomon; Patricia Stephenson; Yiyun Tang; Marileila Varella-Garcia; Keith Wilner; Yung-Jue Bang; Alice T Shaw
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
The lancet oncology 2012;13(10):1011-9.
2012: Kyuichi Kadota; Andre L Moreira; Gregory J Riely; Valerie W Rusch; Camelia S Sima; Kei Suzuki; Prasad S Adusumilli; Stefan S Kachala; Akihiko Yoshizawa; Emily C Zabor; William D Travis
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25(8):1117-27.
2012: Kadoaki Ohashi; Yumei Pan; Gregory J Riely; Lecia V Sequist; Kazuhiko Shien; Shinichi Toyooka; Cindy L Vnencak-Jones; Lu Wang; James Chih-Hsin Yang; Keisuke Aoe; Maria E Arcila; Juliann Chmielecki; Elisa de Stanchina; Dora Dias-Santagata; Jeffrey A Engelman; Lynnette Fernandez-Cuesta; Panos Fidias; Katsuyuki Kiura; Mark G Kris; Marc Ladanyi; Ya-Lun Lin; Vincent A Miller; Teresa Moran; William Pao
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(31):E2127-33.
2012: Maria C Pietanza; Katharine A Price; Gregory J Riely; Kendrith M Rowland; Ravi Salgia; Margaret Tonda; Michael S Wertheim; Christopher G Azzoli; Jan H Beumer; Afshin Dowlati; Shirish M Gadgeel; Mark G Kris; Lee M Krug; Thomas J Lynch; Vincent A Miller; Ben Mitchell; Naiyer A Rizvi
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(5):856-65.
2012: Jamie E Chaft; Marc Ladanyi; Natasha Rekhtman; Gregory J Riely
ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(4):768-9.
2012: M Catherine Pietanza; Gregory J Riely; Naiyer A Rizvi; Camelia S Sima; Dyana K Sumner; William D Travis; Christopher G Azzoli; Timothy A Chan; John J Fiore; Michelle S Ginsberg; Adriana Heguy; Andrei I Holodny; Kety Huberman; Kyuichi Kadota; Mark G Kris; Lee M Krug
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1138-45.
2012: Jamie E Chaft; Maria E Arcila; Marc Ladanyi; Christopher Lau; Paul K Paik; Maria C Pietanza; Gregory J Riely; Valerie Rusch; Camelia S Sima; Maureen F Zakowski; Mark G Kris
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Molecular cancer therapeutics 2012;11(2):485-91.
2011: Gregory J Riely
Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11 Suppl 4):S1803-4.
2011: Carlie S Sigel; Raymond H Thornton; William D Travis; Maureen F Zakowski; Andre L Moreira; Gregory J Riely; Natasha Rekhtman
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11):1849-56.
2011: Paul K Paik; Gregory J Riely; Camelia S Sima; Christopher G Azzoli; Robert T Heelan; Leonard P James; Mark G Kris; Vincent A Miller; Erin Moore; Kenneth K Ng; Naiyer A Rizvi
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
Cancer chemotherapy and pharmacology 2011;68(5):1331-7.
2011: Alice T Shaw; Benjamin J Solomon; Yiyun Tang; Marileila Varella-Garcia; Keith D Wilner; Beow Y Yeap; Yung-Jue Bang; Mohit Butaney; Jeffrey W Clark; Daniel B Costa; Robert C Doebele; Jeffrey A Engelman; Justin Gainor; A John Iafrate; Kimary Kulig; Eunice L Kwak; ROBERT G MAKI; Sai-Hong I Ou; Gregory J Riely; Ravi Salgia; Paulina Selaru; Geoffrey I Shapiro; D Ross Camidge
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
The lancet oncology 2011;12(11):1004-12.
2011: Jamie E Chaft; Mark G Kris; Vincent A Miller; Geoffrey R Oxnard; Camelia S Sima; Gregory J Riely
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6298-303.
2011: Geoffrey R Oxnard; William Pao; Gregory J Riely; Camelia S Sima; Maria E Arcila; Christopher G Azzoli; Yelena Y Janjigian; Samantha L Kass; Mark G Kris; Marc Ladanyi; Vincent A Miller
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6322-8.
2011: William D Travis; Pan-Chyr Yang; Yasushi Yatabe; John H M Austin; David G Beer; Elisabeth Brambilla; Kavita Garg; Kim Geisinger; Michael Gould; Fred R Hirsch; James Jett; Andrew G Nicholson; Masayuki Noguchi; Charles A Powell; Gregory J Riely; Valerie W Rusch
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.
Proceedings of the American Thoracic Society 2011;8(5):381-5.
2011: Geoffrey R Oxnard; Lawrence H Schwartz; Camelia S Sima; Binsheng Zhao; Michelle S Ginsberg; Pingzhen Guo; Leonard P James; Mark G Kris; Robert A Lefkowitz; Gregory J Riely
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3114-9.
2011: Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Melissa L Johnson; Mark G Kris; Lee M Krug; Chanoa Medina; Vincent A Miller; William Pao; Maria C Pietanza; Michelle S Ginsberg
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(8):1435-7.
2011: Melissa L Johnson; Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Mark G Kris; Camelia S Sima; Michelle S Ginsberg; William Pao; Vincent A Miller
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(6):1128-31.
2011: Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2046-51.
2011: Sandra P D'Angelo; Maria C Pietanza; Melissa L Johnson; Gregory J Riely; Vincent A Miller; Camelia S Sima; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2066-70.
2011: Natasha Rekhtman; Suzanne M Brandt; Carlie S Sigel; Maria A Friedlander; Gregory J Riely; William D Travis; Maureen F Zakowski; Andre L Moreira
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(3):451-8.
2011: J Matthew Reinersman; Melissa L Johnson; Gregory J Riely; Dhananjay A Chitale; Anthony D Nicastri; Gerald A Soff; Ann Grossbart Schwartz; Camelia S Sima; Getinet Ayalew; Christopher Lau; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):28-31.
2010: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; David H Johnson; Anne Kessinger; Ritsuko Komaki; Fengming P Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Scott J Swanson; Douglas E Wood; Stephen C Yang
Thymic malignancies.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(11):1302-15.
2010: Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(10):1623-9.
2010: Gregory J Riely; James Huang
Induction therapy for locally advanced thymoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(10 Suppl 4):S323-6.
2010: Nicolas Girard; Julie Teruya-Feldstein; Eden C Payabyab; Gregory J Riely; Valerie W Rusch; Mark G Kris; Maureen F Zakowski
Insulin-like growth factor-1 receptor expression in thymic malignancies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(9):1439-46.
2010: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; David H Johnson; Anne Kessinger; Ritsuko Komaki; Fengming P Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; George R Simon; Scott J Swanson; Douglas E Wood; Stephen C Yang
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(7):740-801.
2010: Wee-Lee Yeo; Gregory J Riely; Beow Y Yeap; Michelle W Lau; Jeremy L Warner; Kelly Bodio; Mark S Huberman; Mark G Kris; Daniel G Tenen; William Pao; Susumu Kobayashi; Daniel B Costa
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1048-53.
2010: Yelena Janjigian; Kevin McDonnell; Mark G Kris; Ronglai Shen; Camelia S Sima; Peter B Bach; Naiyer A Rizvi; Gregory J Riely
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.
Cancer 2010;116(3):670-5.
2010: Nicolas Girard; Emil Lou; Christopher G Azzoli; Rekha Reddy; Mark Robson; Megan Harlan; Irene Orlow; Yasushi Yatabe; Khedoudja Nafa; Marc Ladanyi; Agnes Viale; Mark G Kris; Gregory J Riely; Vincent A Miller; Robert J. Klein; Keitaro Matsuo; William Pao
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):755-63.
2010: David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Janne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):357-60.
2010: Gregory J Riely
Lung cancer in 'Never-smokers': molecular factors trump risk factors.
Oncology (Williston Park, N.Y.) 2010;24(1):38, 40.
2009: Nicolas Girard; Ronglai Shen; Tianhua Guo; Maureen F Zakowski; Adriana Heguy; Gregory J Riely; James Huang; Christopher Lau; Alex E Lash; Marc Ladanyi; Agnes Viale; Cristina R Antonescu; William D Travis; Valerie W Rusch; Mark G Kris; William Pao
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6790-9.
2009: David M Jackman; Vincent A Miller; Leigh-Anne Cioffredi; Beow Y Yeap; Pasi A Janne; Gregory J Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V Sequist; Bruce E Johnson
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5267-73.
2009: James Huang; Nabil P Rizk; William D Travis; Gregory J Riely; Bernard J Park; Manjit S Bains; Joseph Dycoco; Raja M Flores; Robert J Downey; Valerie W Rusch
Comparison of patterns of relapse in thymic carcinoma and thymoma.
The Journal of thoracic and cardiovascular surgery 2009;138(1):26-31.
2009: Binsheng Zhao; Leonard P James; Chaya S Moskowitz; Pingzhen Guo; Michelle S Ginsberg; Robert A Lefkowitz; Yilin Qin; Gregory J Riely; Mark G Kris; Lawrence H Schwartz
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.
Radiology 2009;252(1):263-72.
2009: Gregory J Riely; Jenifer Marks; William Pao
KRAS mutations in non-small cell lung cancer.
Proceedings of the American Thoracic Society 2009;6(2):201-5.
2009: Gregory J Riely; Naiyer A Rizvi; Mark G Kris; Daniel T Milton; David B Solit; Neal Rosen; Emir Senturk; Christopher G Azzoli; Julie R Brahmer; Francis M Sirotnak; Venkatraman E Seshan; Margaret Fogle; Michelle Ginsberg; Vincent A Miller; Charles Rudin
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: James Bean; Gregory J Riely; Marissa Balak; Jenifer L Marks; Marc Ladanyi; Vincent A Miller; William Pao
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7519-25.
2008: Joaquin Garcia; Gregory J Riely; Khedoudja Nafa; Marc Ladanyi
KRAS mutational testing in the selection of patients for EGFR-targeted therapies.
Seminars in diagnostic pathology 2008;25(4):288-94.
2008: Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balazs Halmos; Joo H Kim; Pasi A Janne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7060-7.
2008: Gregory J Riely; Marc Ladanyi
KRAS mutations: an old oncogene becomes a new predictive biomarker.
The Journal of molecular diagnostics : JMD 2008;10(6):493-5.
2008: Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5731-4.
2008: Jenifer L Marks; Ben Golas; Tomas Kirchoff; Vincent A Miller; Gregory J Riely; Kenneth Offit; William Pao
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):805.
2008: Gregory J Riely
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S146-9.
2008: Thomas J Lynch; George R Blumenschein; Jeffrey A Engelman; Igor Espinoza-Delgado; Ramaswamy Govindan; Jeff Hanke; Nasser H Hanna; John V Heymach; Fred R Hirsch; Pasi A Janne; Rogerio Lilenbaum; Ronald B Natale; Gregory J Riely; Lecia V Sequist; Geoffrey I Shapiro; Alice Shaw; Frances A Shepherd; Mark A Socinski; A Gregory Sorensen; Heather A Wakelee; Aaron Weitzman
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S107-12.
2008: Gregory J Riely
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Lung cancer (Amsterdam, Netherlands) 2008;60 Suppl 2():S19-22.
2008: Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
The American journal of surgical pathology 2008;32(6):810-27.
2008: Allan R Li; Dhananjay Chitale; Gregory J Riely; William Pao; Vincent A Miller; Maureen F Zakowski; Valerie W Rusch; Mark G Kris; Marc Ladanyi
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD 2008;10(3):242-8.
2008: Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
2008: Naiyer A Rizvi; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; John Fiore; Gloria Chia; Martin Brower; Robert T Heelan; Michael J Hawkins; Mark G Kris
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):639-43.
2008: James Huang; Gregory J Riely; Kenneth E Rosenzweig; Valerie W Rusch
Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy?
The Annals of thoracic surgery 2008;85(2):365-7.
2007: James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory J Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa N Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi F Gazdar; Harvey I Pass; Valerie W Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent A Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(52):20932-7.
2007: Gregory J Riely; Mark G Kris; Binsheng Zhao; Timothy Akhurst; Daniel T Milton; Erin Moore; Leslie Tyson; William Pao; Naiyer A Rizvi; Lawrence H Schwartz; Vincent A Miller
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5150-5.
2007: Gregory J Riely; Vincent A Miller
Vascular endothelial growth factor trap in non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4623-7.
2007: Thomas J Lynch; Philip D Bonomi; Charles Butts; Angela M Davies; Jeffrey A Engelman; Ramaswamy Govindan; Roy S Herbst; John V Heymach; Bruce E Johnson; Renato G Martins; Roman Perez-Soler; Gregory J Riely; Alan B Sandler; Lecia V Sequist; Mark A Socinski; Kwok-Kin Wong; Carol S Hart
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4583-8.
2007: Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Cancer 2007;110(3):599-605.
2007: Gregory J Riely; Shirish M Gadgeel; Ivan Rothman; Bruce Saidman; Kert Sabbath; Kevie Feit; Mark G Kris; Naiyer A Rizvi
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2007;55(2):181-5.
2006: Gregory J Riely; Katerina Politi; Vincent A Miller; William Pao
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7232-41.
2006: Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6494-501.
2006: Daniel T Milton; Gregory J Riely; William Pao; Vincent A Miller; Mark G Kris; Robert T Heelan
Molecular on/off switch.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4940-2.
2006: Duykhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Venkatraman E Seshan; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1700-4.
2006: Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer A Rizvi; Venkatraman E Seshan; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):839-44.
2005: Gregory J Riely; William Pao
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Cancer biology & therapy 2005;4(10):1096-7.
2005: William Pao; Vincent A Miller; Katerina Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS medicine 2005;2(3):e73.
2005: William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold Varmus
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PLoS medicine 2005;2(1):e17.
2003: Jacob Rachmilewitz; Zipora Borovsky; Gregory J Riely; Robin Miller; Mark L Tykocinski
Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45.
The Journal of biological chemistry 2003;278(16):14059-65.
2002: Jacob Rachmilewitz; Zipora Borovsky; Galit Mishan-Eisenberg; Einat Yaniv; Gregory J Riely; Mark L Tykocinski
Focal localization of placental protein 14 toward sites of TCR engagement.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(6):2745-50.
2001: Jacob Rachmilewitz; Gregory J Riely; J H Huang; Aoshuang Chen; Mark L Tykocinski
A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds.
Blood 2001;98(13):3727-32.
2000: Gregory J Riely; Jacob Rachmilewitz; Peter H Koo; Mark L Tykocinski
alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14.
The Biochemical journal 2000;351 Pt 2():503-8.
1999: Jacob Rachmilewitz; Gregory J Riely; Mark L Tykocinski
Placental protein 14 functions as a direct T-cell inhibitor.
Cellular immunology 1999;191(1):26-33.
1994: M Villa-Garcia; L Li; Gregory J Riely; Paul F Bray
Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene.
Blood 1994;83(3):668-76.